Fatty liver (steatosis) is fat stored in liver cells. Fibrosis is scarring from ongoing injury. They are not the same: you can have a very fatty liver with little scarring, or modest fat with important fibrosis. Fibrosis — not the amount of fat — is what most predicts serious liver outcomes. So the goal isn't to "find fat," it's to find risk.
Section accent: --clay (scoped, in-family). This is the flagship differentiator hub; it also serves the "Fatty Liver: The Complete W8Experts Guide" flagship-article brief.
The idea that organizes this whole section
Don't just find fat. Find risk.
A fatty liver is a common finding. On its own it tells you surprisingly little about your future. The clinically decisive questions are: Is there inflammation and injury (MASH)? Is there scarring (fibrosis)? And what is the metabolic disease driving it? This is the philosophy behind our San Diego metabolic-liver approach — and it's why we separate finding fat from finding risk at every step. → The W8Experts Diagnostic Approach
And its companion: Don't just treat the liver. Treat the metabolic disease behind it. MASLD is a manifestation of metabolic dysfunction; the biggest threat to most patients with MASLD is actually cardiovascular disease, not the liver. → MASLD & Cardiovascular Risk
The words changed — MASLD, MASH (and why)
In 2023, an international consensus renamed the condition to reduce stigma and tie the diagnosis to its cause:
- NAFLD → MASLD — Metabolic dysfunction–Associated Steatotic Liver Disease. Fatty liver linked to metabolic risk factors (excess weight/central adiposity, type 2 diabetes/prediabetes, hypertension, abnormal lipids).
- NASH → MASH — Metabolic dysfunction–Associated Steatohepatitis. The inflammatory, injurious form that can progress.
- New terms also exist for overlap with alcohol (MetALD) — metabolic fatty liver plus meaningful alcohol intake.
The rename matters because it puts the metabolic driver in the name. This isn't a niche liver problem; it's the liver's readout of whole-body metabolic health.
The spectrum — four different things, never conflated
The single most important teaching point on this site's liver pages:
- Steatosis (fat) — fat in liver cells. Common; often low-risk by itself.
- MASH (inflammation/injury) — fat plus inflammation and cell damage. Can progress.
- Fibrosis (scarring) — the liver's scar response to ongoing injury. The strongest predictor of bad outcomes, staged F0–F4.
- Cirrhosis (F4) — advanced, architecture-distorting scarring; raises risk of liver failure and hepatocellular carcinoma (liver cancer).
Fat in the liver ≠ fibrosis in the liver. One patient can have a strikingly fatty liver with minimal fibrosis; another can have modest enzyme abnormalities but clinically important fibrosis. That single mismatch is why enzyme levels and ultrasound "fatty liver" reports are not enough — and why risk stratification exists. → "My Liver Tests Are Normal…"
The pillar map — where to go next
Understand it
- What Is MASLD? — steatosis, MASH, insulin resistance, hepatic fat, fibrosis, cirrhosis, HCC. → /fatty-liver/what-is-masld
- Who Should Be Evaluated? — the risk profile, plus incidental fatty liver on ultrasound/CT/MRI. → /fatty-liver/who-should-be-evaluated
Assess it (the W8Experts pathway)
- The W8Experts Diagnostic Approach — the 4-step signature: identify steatosis → assess metabolic risk → assess fibrosis risk (FIB-4) → second-line noninvasive testing (elastography). → /fatty-liver/diagnostic-approach
- FIB-4 Explained — what it is, how it's read, and its limits (especially age). → /fatty-liver/fib-4
- FibroScan & Elastography — measuring liver stiffness (fibrosis) vs liver fat. → /fatty-liver/elastography
- "My Liver Tests Are Normal — Can I Still Have Fatty Liver Disease?" — yes, and why. → /fatty-liver/normal-enzymes
- Liver Biopsy: When It's Actually Needed — the histologic reference standard, and why most people don't need it. → /fatty-liver/biopsy
Treat it
- Fatty Liver & Weight Loss — dose-dependent benefit; individualized goals. → /fatty-liver/weight-loss
- GLP-1 & Fatty Liver — the Wegovy MASH approval, and fat vs MASH vs fibrosis endpoints. → /fatty-liver/glp1
- MASH Medications — resmetirom, semaglutide, and the pipeline. → /fatty-liver/mash-drugs
- Nutrition for MASLD and Exercise & MASLD — metabolic therapy, not just calories. → /fatty-liver/nutrition · /fatty-liver/exercise
Connect it
- MASLD & Diabetes (bidirectional risk) · MASLD & Cardiovascular Risk (the real leading threat) · Body Composition & MASLD (visceral fat, muscle). → /fatty-liver/diabetes · /fatty-liver/cardiovascular · /fatty-liver/body-composition
- The San Diego Metabolic-Liver Program — the integrated approach. → /fatty-liver/san-diego-program
How common, and why it matters
MASLD is now the most common chronic liver condition, affecting roughly a quarter to a third of adults worldwide and a majority of people with type 2 diabetes or significant obesity. Most people with simple steatosis will never develop advanced liver disease — but a meaningful minority progress to MASH, fibrosis and cirrhosis, and MASLD is a rising cause of liver cancer and transplantation. At the same time, the average person with MASLD is more likely to be harmed by cardiovascular disease than by their liver. Both facts are true, and good care addresses both. → MASLD & Cardiovascular Risk
Is fatty liver reversible?
Often, yes — especially earlier in the spectrum. Liver fat and MASH inflammation respond well to metabolic improvement (weight loss, better glucose control, exercise, and now specific medications). Fibrosis improves more slowly and less predictably; cirrhosis is largely irreversible, though its complications can still be reduced. The honest message: earlier is more reversible, benefit is dose-dependent, and "cure" language is inappropriate — this is metabolic disease management. → Fatty Liver & Weight Loss
SIGNATURE — "What the evidence says: MASLD"
- What we know: Fibrosis stage — not fat amount — drives liver outcomes; metabolic improvement and weight loss reduce liver fat and MASH; semaglutide is now approved for MASH with fibrosis; noninvasive tests (FIB-4 → elastography) can risk-stratify most people without biopsy.
- What we think: Combination metabolic + liver-directed therapy will become standard; cardiovascular risk deserves at least as much attention as the liver.
- What we don't know: The best long-term monitoring intervals, how much fibrosis regression translates to outcomes, and the durability of drug effects on scarring.
- What patients should do: Get risk-stratified (not just labeled), treat the metabolic disease, and don't be reassured by normal enzymes alone.
Questions patients ask
My liver enzymes are normal — can I still have fatty liver disease?
Yes. ALT/AST are not fibrosis tests; significant fibrosis can exist with normal enzymes. Risk is assessed with tools like FIB-4, not enzymes alone. Grade A 🟢 → Normal Enzymes
Is fatty liver the same as MASH?
No. Fatty liver (steatosis) is fat; MASH adds inflammation and injury. Most steatosis isn't MASH. Grade A 🟢
Can thin people get fatty liver?
Yes — "lean MASLD" occurs, often with visceral fat, insulin resistance or genetic factors, so a normal weight doesn't exclude it. Grade B 🟡
Can you have fatty liver without diabetes?
Absolutely — obesity, prediabetes, abnormal lipids, hypertension and central adiposity all drive it. Diabetes raises the risk of progression but isn't required. Grade A 🟢
Can fatty liver turn into cirrhosis?
A minority progresses through MASH and fibrosis to cirrhosis over years; fibrosis stage is the key predictor, which is why we assess it. Grade A 🟢
How much weight loss helps my liver?
Benefit is dose-dependent: roughly ≥5% reduces liver fat, ≥7–10% improves MASH, and larger, sustained loss is needed for fibrosis benefit — individualized, not one-size-fits-all. Grade A 🟢 → Fatty Liver & Weight Loss
Do GLP-1 drugs treat fatty liver?
Semaglutide is FDA-approved for MASH with fibrosis and reduces liver fat and inflammation; effects on scarring are more modest. It doesn't simply "cure" fatty liver. Grade A 🟢 (MASH) / B 🟡 (fibrosis) → GLP-1 & Fatty Liver
Do I need a FibroScan or a biopsy?
Most people are stratified with FIB-4 first, then FibroScan (elastography) if needed; biopsy is reserved for selected uncertain cases. Grade A 🟢 → FIB-4 · Elastography · Biopsy
KEEP READING
- The W8Experts Diagnostic Approach — the 4-step fat-vs-risk pathway.
- FIB-4 Explained and FibroScan & Elastography — the two assessments people confuse.
- GLP-1 & Fatty Liver — what the MASH approval means, honestly.
- MASLD & Cardiovascular Risk — why we treat the patient, not just the liver.
Written by Darius A. Schneider, MD, PhD · Board-Certified Endocrinologist (ECNU) · Last updated: [date] · References: AASLD Practice Guidance on MASLD (2023) and the Nov 2025 semaglutide/MASH update; EASL–EASD–EASO guidance; MASLD/MASH nomenclature consensus (2023); FDA labeling for resmetirom and semaglutide. Regulatory status re-verified on update.
